It is nice to be recognised again and to remain on the shortlist of Healthline’s’ best MS Blogs for 2019.
It is nice to be recognised again and to remain on the shortlist of Healthline’s’ best MS Blogs for 2019.
News from the European Academy of Neurology 2019. Our data is reproducible and oral cladribine does what we said it does. EPO1241 Changes in Lymphocyte subpopulations in Highly Active Multiple Sclerosis patients during Cladribine treatment.M. Ruggieri, C. Gargano, A. Iaffaldano, A. Manni, P. Iaffaldano, D. Paolicelli, M. Trojano; Bari/IT Background and aims: Background: Cladribine tablets 3...
The use of cannabinoids for sleep: A critical review on clinical trials.Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey BN. Exp Clin Psychopharmacol. 2019 May 23. doi: 10.1037/pha0000285. [Epub ahead of print] Cannabis and its pharmacologically active constituents, phytocannabinoids, have long been reported to have multiple medicinal benefits. One association often reported by...
A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. International Multiple Sclerosis Genetics Consortium. Nat Commun. 2019:10(1):2236. Madireddy L, Patsopoulos NA, Cotsapas C, Bos SD, Beecham A, McCauley J, Kim K, Jia X, Santaniello A, Caillier SJ, Andlauer TFM, Barcellos LF, Berge T, Bernardinelli L, Martinelli-Boneschi...
Microglia suppress the secondary progression of autoimmune encephalomyelitis.Tanabe S, Saitoh S, Miyajima H, Itokazu T, Yamashita T. Glia. 2019 May 20. doi: 10.1002/glia.23640. [Epub] So all you will remember here is microglia inhibit secondary progression. They are the good guys. Which is funny because we have been saying they are the bad guys. They report Microglia depletion...
All good things unfortunately come to an end, and sadly this is the last in the series of three on AAN 2019 posters. What has captured my attention from this years AAN has been the varied interests of the clinician scientists who have presented their work here. This is a good sign, because without varied interests, science and ultimately progress slowly comes to a standstill. I call it the...
This was supposed to launch with the Biggest Threat to Science is the Airbrush Post. Read them both for an insight into the science world (CLICK HERE) No-one likes to be rejected at anything in life……Sometimes the output does not cut the mustard and you have to accept it, many times you feel aggreived. You just have to grin and bear it whilst you have to suffer paper after paper of...
This week some of us with decanting to Edinburgh for the annual Association of Neurologists meeting. From an MS perspective, we will have lots to discuss including whether or not the UK MS community has the appetite to take on one, or all of these, studies. Which one do you think is the most important? The SALVAGE study, which is challenging NHS England’s DMT stopping criteria and saying...
You write a paper and maybe get 5minutes of fame, but sadly with time this may get forgotten and this may get airbrushed out of history. Recently, I have been feeling the paint spray as our work on B cells in MS is being forgotten as the big-swingers wake up and tell us all that memory B cells are important, but that gripe is for another day. Today hopefully you are arriving here by following the...
The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, Hamann D, Hintzen RQ. Mult Scler. 2019 May 16:1352458519845112. doi: 10.1177/1352458519845112. [Epub ahead of print] OBJECTIVES: The aim of this study was to assess the Dutch nationwide incidence of myelin...
We propose the very early use of natalizumab to maximise outcomes in people with very early relapsing MS. In the European Union, natalizumab is licensed to treat adults with highly active relapsing-remitting multiple sclerosis for the following patient groups: Patients with highly active disease despite a full and adequate course of treatment with at least one disease-modifying therapy (DMT) or...